Kazia Therapeutics Shares Slide Below 20-Day SMA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 Nov 25
Source: 424B3
Shares of Kazia Therapeutics (KZIA.O) declined sharply today, crossing below their 20-day simple moving average (SMA) as investors reacted to recent developments. The stock, which had surged 51.74% to $8.74 following promising clinical data on metastatic triple-negative breast cancer, faced renewed pressure amid Nasdaq compliance issues. Despite the positive clinical findings, including a notable 86% reduction in tumor burden for a patient treated with paxalisib and pembrolizumab, the company received a notice from Nasdaq regarding non-compliance with market value requirements. Kazia plans to appeal this notice, which may delay any potential suspension or delisting actions, contributing to the stock's bearish momentum today.
Analyst Views on KZIA
Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.930
Low
18.00
Averages
19.00
High
20.00
Current: 7.930
Low
18.00
Averages
19.00
High
20.00
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
